Generic Vizamyl Availability
Last updated on Apr 10, 2025.
Vizamyl is a brand name of flutemetamol f-18, approved by the FDA in the following formulation(s):
VIZAMYL (flutemetamol f-18 - injectable;intravenous)
-
Manufacturer: GE HEALTHCARE
Approval date: October 25, 2013
Strength(s): 40.5mCi/10ML (4.05mCi/ML) (discontinued) [RLD], 121.5mCi/30ML (4.05mCi/ML) [RLD]
Is there a generic version of Vizamyl available?
No. There is currently no therapeutically equivalent version of Vizamyl available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vizamyl. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Patent 7,270,800
Issued: September 18, 2007
Inventor(s): Klunk; William E. et al.
Assignee(s): University of Pittsburgh (Pittsburgh, PA)This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.
Patent expiration dates:
- September 3, 2025✓✓✓
- September 3, 2025
-
Radiopharmaceutical composition
Patent 8,916,131
Issued: December 23, 2014
Inventor(s): Roed Line & Peterson Sarah Elizabeth
Assignee(s): GE Healthcare LimitedThe present invention relates to radiopharmaceuticals and in particular to a radiopharmaceutical composition comprising a compound of Formula (I): and polysorbate as an excipient. The radiopharmaceutical composition of the invention reduces problems encountered with prior art compositions comprising the same class of compounds. Also provided by the invention is a method for the preparation of the radiopharmaceutical composition of the invention as well as particular uses of the radiopharmaceutical composition.
Patent expiration dates:
- September 16, 2028✓
- September 16, 2028
More about Vizamyl (flutemetamol f-18)
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: diagnostic radiopharmaceuticals
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.